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Abstract
Background: Gluten sensitive enteropathy (GSE) is an autoimmune enteropathy triggered by the ingestion of
gluten-containing grains in susceptible individuals. Recurrent aphthous stomatitis (RAS) may be the sole
manifestation of GSE. The aim of this study was to determine the prevalence of gluten sensitivity enteropathy
(GSE) in a large group of patients with RAS and assess the efficacy of gluten free diet (GFD) on the improvement
of aphthous lesions in those who were diagnosed with GSE.
Methods: Two hundred and forty seven patients with RAS were included. The patients had at least three
aphthous attacks per year. Patients were screened by IgA anti-endomysial antibody (EMA), IgA anti tissue
transglutaminase (TTG) and serum IgA level. Those with a positive serology underwent endoscopic biopsies of
the duodenal mucosa and patients with negative serology were excluded. The diagnosis of GSE was based on a
positive serological test and abnormal duodenal histology. For patients w i t h  G S E ,  g l u t e n  f r e e  d i e t  w a s
recommended.
Results: Six out of 247 RAS patients had positive TTG test alone, and one had positive EMA and TTG. All 7
patients with positive serologic tests underwent duodenal biopsies. Histological findings were compatible with
GSE in all of them (Marsh I in four patients, Marsh II in two patients and Marsh IIIB in one another.). The mean
age of GSE patients was 27.42 ± 10.56 (range, 13 to 40) years old. They were suffering from RAS for an average
duration of 4.5 years. All of the 7 GSE patients had not responded to the routine anti-aphthae medications,
including topical corticosteroids, tetracycline and colchicine. Four patients who adhered to a strict gluten-free
diet showed noticeable improvement in their aphthous lesions over a period of 6 months.
Conclusion: A significant minority (e.g. 2.83%) of RAS patients have GSE. This could be compared with the 0.9%
prevalence of GSE in the general population of Iran. This study suggests that evaluation for celiac disease is
appropriate in patients with RAS. Additionally, the unresponsiveness to conventional anti-aphthae treatment
could be an additional risk indicator.
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Background
Gluten sensitive enteropathy (GSE) is an autoimmune
enteropathy triggered by the ingestion of gluten-contain-
ing grains in susceptible individuals. The presentations of
GSE vary clinically, from atypical (without gastrointesti-
nal symptoms), silent and latent to severe forms with gas-
trointestinal and neurological complications. Although
GSE had been identified mainly in individuals of Euro-
pean descent [1], recent data suggests that celiac disease is
a common disorder, not only in populations of European
ancestry, but also in developing areas, such as North
Africa, Middle East and India [2].
Over the past decades, our knowledge on GSE has
improved, and many silent or latent cases of GSE have been
diagnosed by screening with serological tests[3,4]. Early
diagnosis of GSE allows for immediate treatment with a
gluten free diet, restores health, and might prevent the
development of potential complications associated with
GSE (e.g. non-Hodgkin's lymphoma of the gut). [5,6].
Recurrent aphthous stomatitis (RAS) is one of the most
common mucosal diseases Aphthae can affect either gen-
der at any age, although a higher prevalence is noted
among children, adolescents and females [1]. The preva-
lence of RAS in general population is estimated to be at
least 5% [7]. It is one of the important causes of outpa-
tient visits. It has been reported that in 5% of GSE
patients, RAS may be the sole manifestation of the disease
[8].
The association between CD and RAS has been evaluated
in several studies but conflicting results have been
reported [9-11]. Therefore, we conducted this study to
determine the frequency of gluten sensitivity enteropathy
(GSE) in patients with RAS, using relevant serologic as
well as histologic tests. We also aimed to assess the effi-
cacy of gluten free diet (GFD) on the improvement of aph-
thous lesions in those who were diagnosed with GSE
Methods
Over a period of 24 months, all patients with RAS who
attended the Behcet's clinic of Shariati hospital in Tehran
were asked to participate in a screening program for GSE.
Patients included in the study had at least three episodes
of oral aphthae during the year; exclusion criteria were
Behcet's disease, inflammatory bowel disease, systemic
lupus erythematousis, tumors of oral cavity, Reiter syn-
drome and oral lesions due to drugs and radiation. Soft
tissues examination was carried out with conventional
dental chairs, artificial light, flat mirrors, monouse probe
and sterile gauzes. We registered, lesions as RAS if they
match one of these three conditions: clinically confirmed
by physician, referred by patients themselves and reported
by hospital clinical records.
The objectives of the study, as well as the possible necessity
for a small bowel biopsy, were explained to the patients. Of
290 eligible patients, 247 agreed to participate in our study.
Written informed consent was obtained from each partici-
pant, an interviewer completed a clinical questionnaire,
and five-milliliter venous blood sample was obtained from
each patient for serological investigation of GSE.
The study was performed according to the principles of
the Digestive Disease Research Center of Tehran Univer-
sity of Medical Science, and was approved by the Ethics
Committee of this center and Rheumatology research
center of Tehran University of Medical Science.
A complete history of oral aphthous was taken from all
subjects regarding number of aphthous ulcers, duration,
size, precipitating factor, response to conventional ther-
apy (such as topical corticosteroids, tetracycline and col-
chicine) and number of attacks per year.
IgA-Anti endomysial antibody
Serum IgA antibodies against endomysium were meas-
ured by the indirect immunofluorescence method using
commercial kits (Biosystem Madrid, Spain). Briefly,
patient serum is incubated on tissue sections of monkey
esophagus to allow binding of antibodies to the substrate.
Any antibodies not bound are removed by rinsing. Bound
antibodies of the IgA class are detected by incubation of
the substrate with fluorescein-labeled, anti-human immu-
noglobulin conjugate. Reactions are observed under a flu-
orescence microscope equipped with appropriate filters.
The presence of EMA is demonstrated by an apple green
fluorescence of the endomysial lining of smooth muscle
bundles. The titer (the reciprocal of the highest dilution
giving a positive reaction) of the antibody is then deter-
mined by testing serial dilutions.
IgA Tissue transglutaminase antibody
IgA antibodies to tissue transglutaminase were assessed by
ELISA using recombinant human tTG as the antigen (Gen-
esis Diagnostics, Cambridgeshire, UK). Serum samples
were diluted to 1:100 with distilled water, incubated with
antigen for 30 min at room temperature, washed three
times, and subsequently incubated for another 30 min
with antihuman IgA. Optical density was read at 450 nm.
Results were expressed in arbitrary units (AU) according
to the reference calibrator. The cutoff value for a positive
outcome was considered to be 7 AU, according to the
instruction on the kit.
Serum IgA level was measured to rule out IgA deficiency.
Hematology and biochemistry
Complementary hematologic and biochemical investiga-
tions including complete blood count, platelet, erythro-BMC Gastroenterology 2009, 9:44 http://www.biomedcentral.com/1471-230X/9/44
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cyte sedimentation rate, C-reactive protein, serum
sodium, serum potassium, serum calcium, serum phos-
phorous, blood urea nitrogen, creatinine,, cholesterol,
triglyceride, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase, total iron
binding capacity, ferritin, serum iron, stool guaiac exam
(OB), total protein and albumin were performed in
patients who had been diagnosed as GSE.
Duodenal biopsy
Patients with positive serologic test (EMA or tTG) under-
went upper endoscopy and four biopsies were taken from
the second portion of the duodenum.
Each biopsy was oriented over a filter paper as well as
being prepared for standard histological assessment. The
histological assessment included examination for signifi-
cant alteration in main mucosal measurements and lym-
phocytic infiltration, Based on Marsh criteria [12]:
0: Normal mucosal structure without a significant lym-
phocytic infiltration
: Lymphocytic enteritis (more than 30 lymphocytes/100
epithelial cells).
: Lymphocytic enteritis and crypt hyperplasia.
ШA: Partial villous atrophy.
ШB: Subtotal villous atrophy.
ШC: Total villous atrophy.
Gluten-sensitivity enteropathy diagnosis
The presence of positive tTG or EMA plus abnormal duo-
denal histology (Marsh ,  or Ш) was defined as GSE.
Statistical analysis
Data are presented as Mean ± SD or percentage. Statistical
analyses were performed using SPSS software version 15.
Results
One hundred thirty one (e.g. 53%) out of 247 RAS
patients were men. Mean age was 33 ± 11 years old (range,
11 to 66 year old). After serologic studies for GSE, one
patient had positive EMA and tTG tests and six patients
were only tTG positive (four men and three women). All
patients underwent upper GI endoscopy and duodenal
biopsies. In two patients endoscopic finding was compat-
ible with GSE (mild villous atrophy) and five patients had
normal endoscopic view. Pathological finding was com-
patible with Marsh I in four patients, Marsh II in two
patients and Marsh IIIB in one.
The mean age of patients with GSE was 27 ± 10 (from 13
to 40) with a female/male ratio of 3/4. They were suffering
from RAS for an average duration of 4.5 years. All the GSE
patients were unresponsive to previous trials of conven-
tional anti-aphthae drugs (e.g. topical corticosteroids, tet-
racycline and colchicine) (Table 1). Complementary
laboratory tests of these patients were normal except mild
anemia in two patients. None of them complained from
other typical or atypical signs and symptoms of CD.
Four out of the seven GSE started a strict gluten free diet.
One of them had Marsh I, two had Marsh II, and one had
Marsh IIIB lesion. All of them showed a significant
improvement within 2–6 months after beginning of GFD.
Table 1: Characteristics of subjects with positive serologic antibodies for gluten-sensitive enteropathy
Patient no. sex age Duration of 
RAS(y)











1 F 13 2 12< No tTG + II Anemia Yes
2 M 33 5 12< No tTG + I No --
3 F 40 7 6 to12 No tTG + I No ---
4 M 40 6 6 to12 No tTG + I No ----
5 M 18 3 12< No AEA+ & tTG+ III Anemia Yes
6 M 25 5 12< No tTG + I No Yes
7 F 23 4 6 to12 No tTG + II No Yes
tTG: tissue transglutaminase antibody, EMA: anti endomysial antibody.BMC Gastroenterology 2009, 9:44 http://www.biomedcentral.com/1471-230X/9/44
Page 4 of 5
(page number not for citation purposes)
In the four patients, the mean number of attacks of the
aphthous lesions was 6.25 ± 0.96 in the last 6 months pro-
ceeding to GFD and decreased to 1.5 ± 0.58 over the first
6 months of GFD adherence.
Discussion
In this study of a large group of patients with RAS, a 2.83%
prevalence of GSE was observed, as compared with an
estimated prevalence of 0.9% in the general population of
Iran [13].
In order to avoid the controversy in the definition of CD,
we used the term "gluten sensitive enteropathy" rather
than celiac disease to describe patients with any degrees of
intestinal damage together with positive serologic tests.
It has been reported that RAS is at least among the fifth
commonest presentations of CD [14-16]. Furthermore,
oral mucosal lesions or dental enamel defects may be the
sole presenting features of celiac disease [17].
Despite detailed investigations, RAS still has an unknown
etiology and poorly effective management [18,19].
Genetic, immunological and microbial factors may play a
role in the pathogenesis of RAS, whereas attacks may be
precipitated by local trauma, stress, food intake, some
drugs, hormonal changes or vitamin and trace element
deficiencies [19]. RAS can arise in some systemic disorders
including: Behcet's disease [20,21], Sweet's syndrome
[22,23], MAGIC syndrome [24], inflammatory bowel dis-
ease [25,26] and gluten-sensitivity enteropathy (celiac dis-
ease) [27].
The association between RAS and gluten-sensitivity enter-
opathy (GSE) was proposed in 1976 by Ferguson et al [28]
when they found 24% of patients with RAS showed histo-
logical evidence of CD on jejunal biopsy. Nevertheless,
there is still considerable dispute concerning the actual
prevalence of CD among patients with RAS, as different
studies have reported different prevalence of CD in RAS
patients [29-34]. On the other hand in recent years, some
articles are published which expressed little or no signifi-
cant etiological link between RAS and CD, and added that
screening RAS patients for key serological markers of CD
is of little clinical value [10,1]. Currently, there is no
approved recommendation which can be used by clini-
cians to approach patients with RAS regarding celiac dis-
ease. Comparing to the previous studies, this study with a
large group of patients and by using two more sensitive
and specific serologic tests plus duodenal biopsy helped
us reach a reliable conclusion. Prevalence of GSE in
patients with RAS was 2.83%, which is about 3-fold
higher than that expected in general population of Iran
(0.9%) [13].
The effect of gluten-free diet (GFD) on remission of RAS is
still uncertain, as dietary withdrawal of gluten occasion-
ally results in significant benefit whereas some studies
reported it ineffective [11,35,36]. Four patients accepted
to start GFD, and all of them showed a significant
improvement within 2–6 months after beginning of GFD.
Furthermore anemia resolved after 6 months of follow up
in the two patients who suffered from anemia.
Many physicians may still consider the gastrointestinal
signs and symptoms as a main manifestation of celiac
patients whereas recent studies demonstrated that gas-
trointestinal presentations may be absent in GSE patients
especially in the beginning of the disease. In this study,
none of our GSE patients had any gastrointestinal symp-
toms. Therefore, gastrointestinal symptoms are some-
times absent in the setting of the disease and RAS could be
the first or the sole presentation of GSE.
Our study has some limitations. We did not take duode-
nal biopsies from the patients who had negative serologi-
cal tests. It has been reported that the sensitivities of the
serological tests are decreased in GSE patients with minor
mucosal damages [37,38]. We cannot exclude the possi-
bility of missing some GSE patients with negative serolog-
ical tests and Marsh I/II mucosal lesions (e.g. seronegative
GSE). However, a patient with negative serological test
and duodenal mucosal lesion may suffer from other dis-
orders like autoimmune enteropathy, giardiasis, common
variable immunodeficiency, tropical sprue, peptic duo-
denitis, Crohn's disease etc. Including such patients (e.g.
those with negative serological tests with duodenal
mucosal damage) in the spectrum of GSE could increase
the rate of false positive results; unless symptomatic and
histological improvements are confirmed by gluten free
diet. Therefore, in the epidemiological studies, a positive
result from a highly specific serological test (e.g. EMA, or
tTG) together with any degree of duodenal mucosal lesion
provide reasonable criteria for identifying patients with
GSE.
Conclusion
In conclusion, a subset of RAS patients suffers from GSE.
GSE should be considered in RAS patients; unresponsive-
ness to conventional anti-aphthae treatment could be an
additional risk indicator. Implementation of GFD may
prevent the complications of GSE and effectively treat
RAS.
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